Mark W Hahn
CIK 1408502 · Chief Financial Officer · last filed 2026-05-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 100
CHAPEL HILL, NC 27517
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SOLENO THERAPEUTICS INC (SLNO) Delisted | Director | 0 | $53.01 | $0 | $0 | 2 | 2026-05-18 |
| Verona Pharma plc (VRNA) Delisted | Chief Financial Officer | 3,285,280 | $106.91 | $351.23M | -$35.03M | 42 | 2025-10-08 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Chief Financial Officer | 0 | — | — | -$27.9K | 7 | 2019-11-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | EVP and CFO | — | — | — | $0 | 7 | 2017-02-27 |
Recent Filings · Page 3 of 7
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-11-01 | Verona Pharma plc (VRNA) Delisted | Mixed | +754,048 | -$1.04M | EDGAR |
| 2024-10-25 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −144,560 | -$632.8K | EDGAR |
| 2024-10-22 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −525,768 | -$2.30M | EDGAR |
| 2024-10-18 | — | Notice (144) | −100,000 | -$3.47M | EDGAR |
| 2024-09-13 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −600,000 | -$2.25M | EDGAR |
| 2024-09-11 | — | Notice (144) | −75,000 | -$2.10M | EDGAR |
| 2024-08-14 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −400,000 | -$1.28M | EDGAR |
| 2024-08-12 | — | Notice (144) | −50,000 | -$1.13M | EDGAR |
| 2024-08-09 | Verona Pharma plc (VRNA) Delisted | Mixed | +485,200 | -$824.8K | EDGAR |
| 2024-08-05 | Verona Pharma plc (VRNA) Delisted | Tax (F) | −88,544 | -$250.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.